Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does intravesical atropine have equivalent efficacy to oral oxybutynin in the treatment of detrusor overactivity?

Nature Clinical Practice Urology volume 4, pages 538–539 (2007)Cite this article

boxed-textFader M et al. (2007) Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol 177: 208–213

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 (5A Suppl): 33–46

    Article  CAS  Google Scholar 

  2. Haferkamp A and Hohenfellner M (2006) Intravesikale therapie des overactive-bladder-syndroms [German]. Urologe 45: 1283–1288

    Article  CAS  Google Scholar 

  3. Araki I et al. (2003) Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 169: 1384–1387

    Article  Google Scholar 

  4. Litwiller SE et al. (1999) Multiple sclerosis and the urologist. J Urol 161: 743–757

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Tamsin Osborne, Freelance Medical Writer.

Author information

Authors and Affiliations

  1. Neuro-Urology and Voiding Dysfunction in the Department of Urology, AM Arisco is a clinical instructor and is completing her Fellowship in Female Urology, University of Texas Health Science Center, San Antonio, TX, USA.,

    Amy M Arisco

  2. and Associate Professor and Vice Chairman in the Department of Urology, SR Kraus is Head of the Section of Female Urology, Neuro-Urology and Voiding Dysfunction, University of Texas Health Science Center, San Antonio, TX, USA.,

    Stephen R Kraus

Authors
  1. Amy M Arisco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen R Kraus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen R Kraus.

Ethics declarations

Competing interests

SR Kraus received research support from the National Institutes of Health. He is a Consultant, Speaker and receives research support from Pfizer; he is a speaker for Novartis and is a speaker and receives research support from Astellas.

AM Arisco declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arisco, A., Kraus, S. Does intravesical atropine have equivalent efficacy to oral oxybutynin in the treatment of detrusor overactivity?. Nat Rev Urol 4, 538–539 (2007). https://doi.org/10.1038/ncpuro0910

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0910

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing